JP2005132838A - Penicillin crystal and method for producing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a 2β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester (CMPB) crystal having excellent stability. <P>SOLUTION: This crystal is, for example, characterized by an X-ray powder diffraction pattern given by copper radiant rays which are passed through a monochromator and have a λ of 1.5418Å. The crystal is, for example, produced by (A) concentrating a CMPB-containing solution, (B) subjecting the obtained concentrated solution to column chromatography, (C) concentrating the CMPB-containing fraction, and (D) dissolving the obtained CMPB-containing concentrate in an ether solvent and then adding a hydrocarbon solvent to the CMPB-containing solution, so as to make the CMPB crystal precipitated. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to a penicillin crystal and a method for producing the same.

  Formula (1)

で表されるタゾバクタムは、抗菌活性が極めて弱いために、タゾバクタム単独では抗菌剤として使用されることはないが、細菌が産出するβ-ラクタマーゼと不可逆的に結合し、β−ラクタマーゼの活性を阻害する作用を有している。このため、タゾバクタムは、β−ラクタマーゼによって不活性化される既存の各種抗菌剤と併用され、β−ラクタマーゼ産生菌に対して該各種抗菌剤本来の抗菌作用を発揮させることができる（非特許文献１参照）。

Tazobactam represented by the formula is extremely weak in antibacterial activity, so tazobactam alone is not used as an antibacterial agent, but it irreversibly binds to β-lactamase produced by bacteria and inhibits β-lactamase activity Has the effect of For this reason, tazobactam is used in combination with various existing antibacterial agents that are inactivated by β-lactamase, and can exhibit the antibacterial action inherent to the various antibacterial agents against β-lactamase-producing bacteria (Non-patent Document 1).

  2β-Chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester (hereinafter sometimes referred to as “CMPB”) has the formula (2)

[式中、Ｐｈはフェニル基を示す。]
で表される化学構造を有している。

[Wherein Ph represents a phenyl group. ]
It has a chemical structure represented by

As shown in the following reaction formula, tazobactam is produced from CMPB through a 2′-position triazolylation reaction, a 1-position oxidation reaction and a 3-position deesterification reaction of CMPB. Therefore, CMPB is useful as a synthetic intermediate for tazobactam.
Reaction formula

[式中、Ｐｈは前記に同じ。]
ＣＭＰＢは、例えば、２−オキソ−４−（ベンゾチアゾール−２−イル）ジチオ−α−イソプロペニル−１−アゼチジン酢酸ベンズヒドリルとハロゲン化水素酸とを、亜硝酸塩及び／又は亜硝酸エステルの存在下、溶媒中にて反応させる方法（特許文献１参照）、２−オキソ−４−（ベンゾチアゾール−２−イル）ジチオ−α−イソプロペニル−１−アゼチジン酢酸ベンズヒドリルと塩化銅とを溶媒中にて反応させる方法（特許文献２参照）等により製造されている。

[Wherein Ph is the same as defined above. ]
CMPB is, for example, 2-oxo-4- (benzothiazol-2-yl) dithio-α-isopropenyl-1-azetidine acetate benzhydryl and hydrohalic acid in the presence of nitrite and / or nitrite. , A method of reacting in a solvent (see Patent Document 1), 2-oxo-4- (benzothiazol-2-yl) dithio-α-isopropenyl-1-azetidine acetate benzhydryl and copper chloride in a solvent It is manufactured by a method of reacting (see Patent Document 2) or the like.

  CMPB obtained by the method described in Patent Document 1 and Patent Document 2 is an oily substance (see Comparative Example 1 and Comparative Example 2 below). This CMPB is unstable because it has a halogen atom that is easily desorbed in the molecule. Therefore, for example, if the CMPB obtained by the above method is stored at room temperature (room temperature), it decomposes within a relatively short period of time. Therefore, there is a disadvantage that the quality is remarkably deteriorated.

Synthetic intermediates for pharmaceuticals have excellent stability that can maintain high quality over a long period of time without causing substantial degradation or alteration under mild and economical conditions such as storage at room temperature. It is hoped that Therefore, CMPB is also desired to have excellent stability as described above.
Japanese Patent No. 2602669 U.S. Pat. No. 4,496,484 Handbook of the latest antibiotics, 10th edition, Katsuharu Sakai, page 113

  An object of the present invention is to provide a CMPB crystal excellent in stability.

  As a result of intensive studies to solve the above problems, the present inventors have concentrated a solution containing CMPB, subjected the resulting concentrate to column chromatography, concentrated the resulting CMPB-containing fraction, and obtained further. By treating the resulting CMPB-containing concentrate with a specific solvent, CMPB crystals having excellent stability were successfully extracted. The present invention has been completed based on such findings.

The present invention provides the following inventions 1 to 4.
1.2 Crystals of β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester.
2. 2. The crystal as described in 1 above, having a peak at each lattice spacing shown below in an X-ray powder diffraction pattern obtained with a copper radiation of λ = 1.5418 through a monochromator.

d (lattice spacing)
7.27-8.16
5.36-5.93
4.44 to 4.92
3.64 to 4.37
3. 2. The crystal as described in 1 above, having a peak at each lattice spacing shown below in an X-ray powder diffraction pattern obtained with a copper radiation of λ = 1.5418 through a monochromator.

d (lattice spacing)
7.2787-88.177
5.3646-5.9292
4.4430-4.9106
3.6423-4.3602
4). (A) a step of concentrating a solution containing 2β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester (CMPB);
(B) subjecting the resulting concentrate to column chromatography,
2C-chloro comprising the steps of (C) concentrating the CMPB-containing fraction, and (D) dissolving the resulting CMPB-containing concentrate in an ether solvent and then adding a hydrocarbon solvent to the solution to precipitate CMPB crystals. A process for producing methyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester crystals.

  The CMPB crystal of the present invention is produced, for example, by performing the steps (A) to (D).

Step A The solution containing CMPB used in this step is known, and includes, for example, a reaction solution containing CMPB obtained according to the method described in Patent Document 1, Patent Document 2, and the like.

  A well-known concentration means can be widely applied to the concentration of the solution containing CMPB. Examples of such a concentration means include vacuum concentration. The temperature during the concentration is preferably −10 to 30 ° C., more preferably 15 to 25 ° C. so as not to exceed 50 ° C.

  The concentration level of the solution containing CMPB is preferably set to a level that does not hinder the purification process by column chromatography in the next step B.

  In the present invention, it is desirable to remove insoluble matter from the solution containing CMPB by filtration prior to concentration in step A.

Step B: The concentrate obtained in step A is purified by column chromatography.

  In this step, known column chromatography can be used, and examples thereof include column chromatography using silica gel.

  The silica gel is not particularly limited, and commercially available products such as Wakogel C-200 (manufactured by Wako Pure Chemical Industries, Ltd.) and silica gel (Silicagel) 60 (manufactured by Merck) can be widely used.

  The amount of silica gel used varies depending on the column diameter to be used and cannot be generally specified, but is usually about 2 to 200 parts by weight, preferably about 10 to 100 parts by weight with respect to 1 part by weight of CMPB subjected to column treatment.

  As a developing solvent, a solvent usually used in column chromatography can be widely used. For example, aromatic hydrocarbons such as benzene and toluene; esters such as methyl acetate and ethyl acetate; acetone, methyl ethyl ketone and di-n -Ketones such as butyl ketone; Acetonitrile; Halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform and carbon tetrachloride; Ethers such as diethyl ether, dioxane and tetrahydrofuran; Aliphatic hydrocarbons such as n-hexane; Cycloaliphatics such as cyclohexane A hydrocarbon etc. are mentioned. These solvents can be used alone or in combination of two or more in an appropriate ratio.

  A preferred developing solvent is a mixed solvent of ethyl acetate and benzene. The volume ratio of ethyl acetate / benzene is usually about 1/10 to about 1/30, preferably about 1/15 to about 1/25.

  The usage amount of the developing solvent is appropriately selected according to the amount of CMPB to be treated, the usage amount of silica gel, the type of the developing solvent, and the like.

  The CMPB-containing fractions obtained in this step are combined and used for the next C step.

The CMPB-containing fraction obtained in step C and step B is concentrated by a known concentration means. Examples of such a concentration means include vacuum concentration. The temperature during the concentration is preferably −10 to 30 ° C., more preferably 15 to 25 ° C. so as not to exceed 50 ° C.

  In concentrating the CMPB-containing fraction, it is desirable to remove the solvent in the fraction as much as possible. For example, the amount of solvent contained in the CMPB-containing concentrate is 80% by volume or less, preferably 60% by volume or less, more preferably 50% by volume. It is good to concentrate so that it may become less than%.

The CMPB-containing concentrate obtained in Step D and Step C is dissolved in an ether solvent, and then a hydrocarbon solvent is added to this solution to precipitate CMPB crystals.

  As the ether solvent, known ether solvents that can dissolve CMPB can be widely used. Preferred ether solvents include diethyl ether and diisopropyl ether. An ether solvent is used individually by 1 type or in mixture of 2 or more types.

  The amount of the ether solvent used may be an amount that can dissolve the CMPB-containing concentrate in the ether solvent, and is usually about 0.5 to 5 liters, preferably 0.80, with respect to 1 kg of CMPB in the CMPB-containing concentrate. About 3 liters may be used. Moreover, it is preferable to use an ether solvent so that it may become equal volume or more with respect to the solvent contained in a CMPB containing concentrate.

  The temperature at which the CMPB-containing concentrate is dissolved in an ether solvent is usually about −30 to 50 ° C., preferably about −10 to 30 ° C.

  As the hydrocarbon solvent, known hydrocarbon solvents that do not readily dissolve CMPB can be widely used. Examples of such a hydrocarbon solvent include aliphatic hydrocarbons such as n-pentane, n-hexane, n-heptane, and n-octane, and alicyclic hydrocarbons such as cyclohexane. Among these, aliphatic hydrocarbons are preferable, and n-hexane is more preferable.

  The amount of the hydrocarbon solvent used may be an amount in which CMPB is precipitated, and is usually about 0.1 to 20 times by weight, preferably about 0.5 to 10 times by weight with respect to the used ether solvent. Add gradually.

  The temperature at which the hydrocarbon solvent is added is usually about −30 to 50 ° C., preferably about −10 to 30 ° C. from the viewpoint of crystallization efficiency.

  The CMPB crystal produced by crystallization is separated from the ether solvent and the hydrocarbon solvent by a known separation operation. Examples of the separation operation include a filtration operation and a centrifugation operation. The filtration operation may be performed under normal pressure, increased pressure, or reduced pressure.

  In the method of the present invention, it is desirable to perform the series of operations of the above-described A process to D process continuously as quickly as possible.

  Although the CMPB crystal of the present invention has a halogen atom that is easily desorbed in its molecule, it is stable without being substantially decomposed or altered even when stored at room temperature for a long period of one month or longer. And can maintain high quality.

  Further, in a solution obtained by dissolving the CMPB crystal of the present invention in an organic solvent such as methylene chloride, CMPB is extremely stable over a long period of time and substantially does not decompose. Therefore, for example, when the CMPB crystal of the present invention is used for the 2′-position triazolylation reaction of CMPB shown in the above reaction formula, the yield of the target triazolylation product can be increased.

  Therefore, the CMPB crystal of the present invention can be suitably used as a synthetic intermediate for pharmaceuticals such as tazobactam.

  The present invention will be further clarified with reference examples, examples, comparative examples and test examples.

Reference example 1
2-Oxo-4- (benzothiazol-2-yl) dithio-α-isopropenyl-1-azetidine acetic acid benzhydryl ester (45.8 g) in dichloromethane (240 ml) was added with ice-cooled 35% hydrochloric acid (48.6 ml) and 5 ° C. 48.5 ml of cold water was added, then 18 ml of 36% aqueous sodium nitrite solution was added dropwise over 30 minutes. The mixture was stirred for 1 hour under ice-cooling, the precipitate was removed by filtration, and the organic layer of the filtrate was separated. The organic layer was washed twice with cold water and dried over magnesium sulfate, and then the organic layer was concentrated under reduced pressure to obtain 40 g of a foam.

This foam was confirmed to be CMPB from the ¹ H-NMR spectrum. This foam was found to be amorphous because a clear X-ray powder diffraction pattern could not be obtained with copper radiation of λ = 1.54182 mm through a monochromator.

  FIG. 1 shows an X-ray powder diffraction pattern of the foam.

Example 1
Process A:
2-Oxo-4- (benzothiazol-2-yl) dithio-α-isopropenyl-1-azetidine acetic acid benzhydryl ester (45.8 g) in dichloromethane (240 ml) was added with ice-cooled 35% hydrochloric acid (48.6 ml) and 5 ° C. 48.5 ml of cold water was added, then 18 ml of 36% aqueous sodium nitrite solution was added dropwise over 30 minutes. The mixture was stirred for 1 hour under ice-cooling, the precipitate was removed by filtration, and the organic layer of the filtrate was separated. The organic layer was washed twice with cold water and dried over magnesium sulfate, and then the organic layer was concentrated under reduced pressure so that the amount of methylene chloride was 40 ml.

Process B:
The resulting concentrate was subjected to silica gel chromatography (filler: Wako Gel C-200, 1 kg used; developing solvent: benzene / ethyl acetate = 20/1 (volume ratio)) to obtain a CMPB-containing fraction. These CMPB-containing fractions were combined.

Process C:
The combined CMPB-containing fractions were immediately concentrated under reduced pressure at 20 ° C. until the amount of solvent in the concentrate was about 10% by volume.

Step D:
Crystals were precipitated by adding 50 ml of diethyl ether to the resulting CMPB-containing concentrate at 20 ° C. to make a solution, and gradually adding 100 ml of n-hexane thereto.

  The precipitated crystals were taken out by vacuum filtration, washed with n-hexane, and dried under reduced pressure at room temperature. The yield was 16.4g.

From the ¹ H-NMR spectrum, the obtained crystal was confirmed to be CMPB.
¹ H-NMR (300 MHz, CDCl ₃ , δ ppm):
1.33 (s, 3H), 3.12 (dd, J = 2 Hz, 16 Hz, 1H), 3.60 (s, 1H), 3.61 (dd, J = 4 Hz, 16 Hz, 1H), 5. 13 (s, 1H), 5.26, 5.34 (ABq, J = 13 Hz, 2H), 5.41 (dd, J = 2 Hz, 4 Hz, 1H), 7.25-7.40 (m, 10H) )
With respect to this crystal, an X-ray powder diffraction pattern obtained with a copper radiation of λ = 1.5418 through a monochromator was measured. As a result, the following clear X-ray pattern was obtained.

d (lattice spacing) relative intensity (I / I _o )
9.461 0.21
7.769 0.50
7.662 0.51
6.506 0.35
5.647 1.00
5.248 0.29
4.761 0.30
4.677 0.40
4.358 0.25
4.275 0.28
4.153 0.51
3.907 0.19
3.834 0.36
3.448 0.26
3.200 0.19
FIG. 2 shows an X-ray powder diffraction pattern of the crystal.

Comparative Example 1
Acetone was added to 20 g of the foam solid obtained in the same manner as in Reference Example 1, the foam solid was dissolved in acetone, and insoluble matters were removed by filtration. The filtrate was concentrated, and 25 ml of diethyl ether was added to the resulting concentrate to attempt crystallization.

  However, no solid deposition was observed and the solution remained homogeneous. Further, n-hexane was gradually added to this solution, but no solid precipitation was observed, and an oily substance was finally released.

Comparative Example 2
40 g of the foam obtained in Reference Example 1 was immediately dissolved in 40 ml of dichloromethane, and silica gel chromatography (filler: Wakogel C-200, 1 kg used; developing solvent: benzene / ethyl acetate = 20/1 (volume ratio)) The CMPB-containing fraction was immediately concentrated at 20 ° C. under reduced pressure to give an oil.

This oily substance was confirmed to be CMPB from ¹ H-NMR spectrum.

Test example 1
After 5 g of CMPB crystals (purity 100%) of Example 1 and 5 g of CMPB amorphous (purity 99.2%) of Reference Example 1 were put in test tubes, sealed, and stored at room temperature (20-30 ° C.) for 1 month. Their purity was examined. The purity was measured by liquid chromatography.

  As a result, it was found that the purity of the CMPB crystal of Example 1 was 95%, it was stable without substantial decomposition or alteration, and high quality could be maintained. On the other hand, the purity of the CMPB amorphous material of Reference Example 1 was 67%, which revealed that the stability was poor.

Test example 2
1 g of CMPB crystal (purity 97%, the CMPB crystal of Example 1 stored at room temperature (about 25 ° C.) for 20 days) and CMPB amorphous (78% purity, CMPB crystal of Reference Example 1 at room temperature (about 25 days) 1.244 g was stored as a test sample.

  Each of these samples was put in a flask, 10 ml of methylene chloride was added and dissolved, and then sealed. A solution obtained by dissolving the CMPB sample in methylene chloride was stirred at room temperature (about 25 ° C.), and the amount of CMPB remaining in the solution after 3.5 hours and 6 hours was measured by liquid chromatography. The amount of CMPB in the CMPB crystal before the test or the amount of CMPB in the CMPB amorphous was compared.

  As a result, the amount of CMPB after 3.5 hours and the amount of CMPB after 6 hours in a solution obtained by dissolving a CMPB crystal sample in methylene chloride are exactly the same as the amount of CMPB in the first CMPB crystal. It was not decomposed in. In contrast, the amount of CMPB after 3.5 hours and the amount of CMPB after 6 hours in a solution obtained by dissolving a CMPB amorphous sample in methylene chloride are 86.8 respectively based on the amount of CMPB in the first CMPB amorphous. %, 63.4%, and it was revealed that CMPB was gradually decomposed in methylene chloride.

FIG. 1 is an X-ray powder diffraction pattern of the foam obtained in Reference Example 1. FIG. 2 is an X-ray powder diffraction pattern of the CMPB crystal obtained in Example 1.

Claims (4)

  Crystals of 2β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester. 2. The crystal according to claim 1, which has a peak at each lattice spacing shown below in an X-ray powder diffraction pattern obtained with a copper radiation of λ = 1.5418 through a monochromator.
d (lattice spacing)
7.27-8.16
5.36-5.93
4.44 to 4.92
3.64 to 4.37 The crystal according to claim 1, having a peak at each lattice spacing shown below in an X-ray powder diffraction pattern obtained with a copper radiation of λ = 1.5418 through a monochromator.
d (lattice spacing)
7.2787-88.177
5.3646-5.9292
4.4430-4.9106
3.6423-4.3602 (A) a step of concentrating a solution containing 2β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester (CMPB);
(B) subjecting the resulting concentrate to column chromatography,
2C-chloro comprising the steps of (C) concentrating the CMPB-containing fraction, and (D) dissolving the resulting CMPB-containing concentrate in an ether solvent and then adding a hydrocarbon solvent to the solution to precipitate CMPB crystals. A process for producing methyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester crystals.

Images